Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q1 Report 2020

May 5, 2020

Investor presentations

Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020

Investor Presentation May 2020

JP Morgan Healthcare Conference, San Francisco, 15th January 2020

Linzagolix Phase 3 PRIMROSE 2 Trial Results

Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019

Investor Presentation November 2019

Cantor Global Healthcare Conference October 4 2019

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

1 2

Press Releases

ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

press release

July 3, 2020

Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…

Read more

ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA

press release

July 1, 2020

Geneva, Switzerland and Boston, MA – July 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN – a clinical-stage biopharmaceutical…

Read more

ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids

press release

June 29, 2020

Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more
1 2 3 50

General Meetings

ObsEva Annual General Meeting 2020

June 9, 2020

Read more

ObsEva Annual General Meeting 2019

May 8, 2019

Read more
1 2 3

Upcoming Events

Year End 2020 Financial Results week of 01 March 2021

Event

March 1, 2021


Read more

Q3 2020 Financial Results week of 02 November 2020

Event

November 2, 2020


Read more

Half Year 2020 Financial Results week of 03 August 2020

Event

August 3, 2020


Read more
1 2
 

Contacts

ObsEva Switzerland Office

+41 (0)22 552 3840


contact@obseva.ch

ObsEva U.S. Office

+1 857 972 9364


contact@obseva.ch

Media Switzerland & Europe

Mario Corso

Vice President, Investor Relations

+1 857 972 9347 Office

+1 781 366 5726 Mobile

mario.corso@obseva.com

Media United States

Mario Corso

Vice President, Investor Relations

+1 857 972 9347 Office

+1 781 366 5726 Mobile

mario.corso@obseva.com

Investor relations




ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.

 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue